Cd36 as a multiple-ligand signaling receptor in atherothrombosis

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2011, Pages 42-55

  Nergiz Unal, R ^a   Rademakers, T ^b   Cosemans, J M M ^a   Heemskerk, J W M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherothrombosis; Lipoproteins; Macrophages; Monocytes; Thrombospondin

Indexed keywords

CALCIUM ION; CD36 ANTIGEN; COLLAGEN RECEPTOR; COLLAGEN TYPE 1; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GLUCOSE TRANSPORTER 4; HEXARELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONG CHAIN FATTY ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; PROTEIN TYROSINE KINASE; RHO FACTOR; STRESS ACTIVATED PROTEIN KINASE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; ARTICLE; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; BINDING SITE; CARDIOMYOPATHY; CELLULAR IMMUNITY; DEGRANULATION; ENDOCYTOSIS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ERYTHROCYTE; FATTY ACID TRANSPORT; FIBROBLAST; FOAM CELL; GENE MUTATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART MUSCLE CELL; HUMAN; HYPERLIPIDEMIA; INTRACELLULAR SIGNALING; LIGAND BINDING; LIPID METABOLISM; LIPID STORAGE; MACROPHAGE; MACROPHAGE FUNCTION; METABOLIC SYNDROME X; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PLASMODIUM FALCIPARUM; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS;

ANIMALS; ANTIGENS, CD36; ATHEROSCLEROSIS; FATTY ACIDS; HUMANS; LIPOPROTEINS; SIGNAL TRANSDUCTION; THROMBOSIS; THROMBOSPONDIN 1;

EID: 79952720293     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152511794182855     Document Type: Article

References (177)

1. Greenwalt, D.E.; Lipsky, R.H.; Ockenhouse, C.F.; Ikeda, H.; Tandon, N.N.; Jamieson, G.A. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood, 1992, 80(5), 1105-1115.
2. Ikeda, H. Platelet membrane protein CD36. Hokkaido Igaku Zasshi 1999, 74(2), 99-104.
3. Febbraio, M.; Silverstein, R.L. CD36: implications in cardiovascular disease. Int. J. Biochem. Cell Biol., 2007, 39(11), 2012-2030.
4. Valiyaveettil, M.; Podrez, E.A. Platelet hyperreactivity, scavenger receptors and atherothrombosis. J. Thromb. Haemost., 2009, (7 Suppl. 1), 218-221.
5. Silverstein, R.L.; Febbraio, M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci. Siganl., 2010, 2, 272-273.
6. Shattil, S.J.; Brugge, J.S. Protein tyrosine phosphorylation and the adhesive functions of platelets. Curr. Opin. Cell Biol., 1991, 3(5), 869-879.
7. Berger, G.; Caen, J.P.; Berndt, M.C.; Cramer, E.M. Ultrastructural demonstration of CD36 in the alpha-granule membrane of human platelets and megakaryocytes. Blood, 1993, 82(10), 3034-3044.
8. Vega, M.A.; Segui-Real, B.; Garcia, J.A.; Cales, C.; Rodriguez, F.; Vanderkerckhove, J.; Sandoval, I.V. Cloning, sequencing, and expression of a cDNA encoding rat LIMP II, a novel 74-kDa lysosomal membrane protein related to the surface adhesion protein CD36. J. Biol. Chem., 1991, 266(25), 16818-16824.
9. Hart, K.; Wilcox, M. A Drosophila gene encoding an epithelial membrane protein with homology to CD36/LIMP II. J. Mol. Biol., 1993, 234(1), 249-253.
10. Acton, S.; Rigotti, A.; Landschulz, K.T.; Xu, S.; Hobbs, H.H.; Krieger, M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science, 1996, 271(5248), 518-520.
11. Hoosdally, S.J.; Andress, E.J.; Wooding, C.; Martin, C.A.; Linton, K.J. The human scavenger receptor CD36: glycosylation status and its role in trafficking and function. J. Biol. Chem., 2009, 284(24), 16277-16288.
12. Gruarin, P.; Sitia, R.; Alessio, M. Formation of one or more in-trachain disulphide bonds is required for the intracellular processing and transport of CD36. Biochem. J., 1997, 328, 635-642.
13. Tao, N.; Wagner, S.J.; Lublin, D.M. CD36 is palmitoylated on both N-and C-terminal cytoplasmic tails. J. Biol. Chem., 1996, 271(37), 22315-22320.
14. Rasmussen, J.T.; Berglund, L.; Rasmussen, M.S.; Petersen, T.E. Assignment of disulfide bridges in bovine CD36. Eur. J. Biochem., 1998, 257(2), 488-494.
15. Collot-Teixeira, S.; Martin, J.; McDermott-Roe, C.; Poston, R.; McGregor, J.L. CD36 and macrophages in atherosclerosis. Cardio-vasc. Res., 2007, 75(3), 468-477.
16. Asch, A.S.; Liu, I.; Briccetti, F.M.; Barnwell, J.W.; Kwakye-Berko, F.; Dokun, A.; Goldberger, J.; Pernambuco, M. Analysis of CD36 binding domains: ligand specificity controlled by dephosphoryla-tion of an ectodomain. Science, 1993, 262(5138), 1436-1440.
17. Prater, C.A.; Plotkin, J.; Jaye, D.; Frazier, W.A. The properdin-like type I repeats of human thrombospondin contain a cell attachment site. J. Cell Biol., 1991, 112(5), 1031-1040.
18. Pearce, S.F.; Wu, J.; Silverstein, R.L. A carboxyl terminal truncation mutant of CD36 is secreted and binds thrombospondin: evidence for a single transmembrane domain. Blood, 1994, 84(2), 384-9.
19. Frieda, S.; Pearce, A.; Wu, J.; Silverstein, R.L. Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36. J. Biol. Chem., 1995, 270(7), 2981-2986.
20. Simantov, R.; Febbraio, M.; Crombie, R.; Asch, A.S.; Nachman, R.L.; Silverstein, R.L. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J. Clin. Invest., 2001, 107(1), 45-52.
21. Febbraio, M.; Hajjar, D.P.; Silverstein, R.L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest., 2001, 108(6), 785-791.
22. Kar, N.S.; Ashraf, M.Z.; Valiyaveettil, M.; Podrez, E.A. Mapping and characterization of the binding site for specific oxidized phos-pholipids and oxidized low density lipoprotein of scavenger receptor CD36. J. Biol. Chem., 2008, 283(13), 8765-8771.
23. Puente Navazo, M.D.; Daviet, L.; Ninio, E.; McGregor, J.L. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL). Arterioscler. Thromb. Vasc. Biol., 1996, 16(8), 1033-1039.
24. Bodart, V.; Febbraio, M.; Demers, A.; McNicoll, N.; Pohankova, P.; Perreault, A.; Sejlitz, T.; Escher, E.; Silverstein, R.L.; Lamon-tagne, D.; Ong, H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ. Res., 2002, 90(8), 844-849.
25. Demers, A.; McNicoll, N.; Febbraio, M.; Servant, M.; Marleau, S.; Silverstein, R.; Ong, H. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem. J., 2004, 382(Pt 2), 417-424.
26. Abumrad, N.A.; el-Maghrabi, M.R.; Amri, E.Z.; Lopez, E.; Gri-maldi, P.A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem., 1993, 268(24), 17665-17668.
27. Baillie, A.G.; Coburn, C.T.; Abumrad, N.A. Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog. J. Membr. Biol., 1996, 153(1), 75-81.
28. Rhainds, D.; Brissette, L. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int. J. Biochem. Cell Biol., 2004, 36(1), 39-77.
29. Daviet, L.; Malvoisin, E.; Wild, T.F.; McGregor, J.L. Throm-bospondin induces dimerization of membrane-bound, but not soluble CD36. Thromb. Haemost., 1997, 78(2), 897-901.
30. Hatmi, M.; Gavaret, J.M.; Elalamy, I.; Vargaftig, B.B.; Jacquemin, C. Evidence for cAMP-dependent platelet ectoprotein kinase activity that phosphorylates platelet glycoprotein IV (CD36). J. Biol. Chem., 1996, 271(40), 24776-24780.
31. Tandon, N.N.; Kralisz, U.; Jamieson, G.A. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J. Biol. Chem., 1989, 264(13), 7576-7583.
32. Diaz-Ricart, M.; Tandon, N.N.; Carretero, M.; Ordinas, A.; Bastida, E.; Jamieson, G.A. Platelets lacking functional CD36 (glyco-protein IV) show reduced adhesion to collagen in flowing whole blood. Blood, 1993, 82(2), 491-496.
33. Beer, J.H.; Rabaglio, M.; Berchtold, P.; von Felten, A.; Clemetson, K.J.; Tsakiris, D.A.; Kehrel, B.; Brandenberger, S. Autoantibodies against the platelet glycoproteins (GP) IIb/IIIa, Ia/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction. Blood, 1993, 82(3), 820-829.
34. Matsuno, K.; Diaz-Ricart, M.; Montgomery, R.R.; Aster, R.H.; Jamieson, G.A.; Tandon, N.N. Inhibition of platelet adhesion to collagen by monoclonal anti-CD36 antibodies. Br. J. Haematol., 1996, 92(4), 960-967.
35. Nieswandt, B.; Brakebusch, C.; Bergmeier, W.; Schulte, V.; Bouvard, D.; Mohtari-Nejad, R.; Lindhout, T.; Heemskerk, J.W.M.; Zirngibl, H.; Fässler, R. Glycoprotein VI but not a2b1 integrin is essential for platelet interaction with collagen. EMBO J., 2001, 20, 2120-2130.
36. Lecut, C.; Schoolmeester, A.; Kuijpers, M.J.E.; Broers, J.L.V.; van Zandvoort, M.A.M.J.; Vanhoorelbeke, K.; Deckmyn, H.; Jandrot-Perrus, M.; Heemskerk, J.W.M. Principal role of glycoprotein VI in a2b1 and aIIbb3 activation during collagen-induced thrombus formation. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1727-1733.
37. Siljander, P.R.M.; Munnix, I.C.A.; Smethurst, P.A.; Deckmyn, H.; Lindhout, T.; Ouwehand, W.H.; Farndale, R.W.; Heemskerk, J.W.M. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood, 2004, 103, 1333-1341.
38. Munnix, I.C.; Kuijpers, M.J.; Auger, J.; Thomassen, C.M.; Panizzi, P.; van Zandvoort, M.A.; Rosing, J.; Bock, P.E.; Watson, S.P.; Heemskerk, J.W. Segregation of platelet aggregatory and proco-agulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler. Thromb. Vasc. Biol., 2007, 27(11), 2484-2490.
39. Kuijpers, M.J.E.; Pozgajova, M.; Cosemans, J.M.E.M.; Munnix, I.C.A.; Eckes, B.; Nieswandt, B.; Heemskerk, J.W.M. Role of murine integrin a2ß1 in thrombus stabilization and embolization: contribution of thromboxane A2. Thromb.Haemost., 2007, 98, 1072-1080.
40. Nieswandt, B.; Watson, S.P. Platelet-collagen interaction: is GPVI the central receptor? Blood, 2003, 102, 449-461.
41. Yamamoto, N.; Akamatsu, N.; Yamazaki, H.; Tanoue, K. Normal aggregations of glycoprotein IV (CD36)-deficient platelets from seven healthy Japanese donors. Br. J. Haematol., 1992, 81(1), 86-92.
42. Saelman, E.U.; Kehrel, B.; Hese, K.M.; de Groot, P.G.; Sixma, J.J.; Nieuwenhuis, H.K. Platelet adhesion to collagen and endothelial cell matrix under flow conditions is not dependent on platelet glycoprotein IV. Blood, 1994, 83(11), 3240-3244.
43. Daniel, J.L.; Dangelmaier, C; Strouse, R.; Smith, J.B. Collagen induces normal signal transduction in platelets deficient in CD36 (platelet glycoprotein IV). Thromb. Haemost., 1994, 71(3), 353-356.
44. Kehrel, B.; Wierwille, S.; Clemetson, K.J.; Anders, O.; Steiner, M.; Knight, CG.; Farndale, R.W.; Okuma, M.; Barnes, M.J. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood, 1998, 91(2), 491-499.
45. Kehrel, B.; Kronenberg, A.; Rauterberg, J.; Niesing-Bresch, D.; Niehues, U.; Kardoeus, J.; Schwippert, B.; Tschope, D.; van de Loo, J.; Clemetson, K.J. Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V. Blood, 1993, 82(11), 3364-3370.
46. Janabi, M.; Yamashita, S.; Hirano, K.; Matsumoto, K.; Sakai, N.; Hiraoka, H.; Kashiwagi, H.; Tomiyama, Y.; Nozaki, S.; Matsu-zawa, Y. Reduced adhesion of monocyte-derived macrophages from CD36-deficient patients to type I collagen. Biochem. Biophys. Res. Commun., 2001, 283(1), 26-30.
47. Tan, K.; Lawler, J. The interaction of Thrombospondins with extracellular matrix proteins. J. Cell Commun. Signal., 2009, 3(3-4), 177-187.
48. Bornstein, P. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest., 2001, 107(8), 929-934.
49. Kyriakides, T.R.; Zhu, Y.H.; Smith, L.T.; Bain, S.D.; Yang, Z.; Lin, M.T.; Danielson, K.G.; Iozzo, R.V.; LaMarca, M.; McKinney, C.E.; Ginns, E.I.; Bornstein, P. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol., 1998, 140(2), 419-430.
50. Aiken, M.L.; Ginsberg, M.H.; Byers-Ward, V.; Plow, E.F. Effects of OKM5, a monoclonal antibody to glycoprotein IV, on platelet aggregation and thrombospondin surface expression. Blood, 1990, 76(12), 2501-2509.
51. Jurk, K.; Clemetson, K.J.; de Groot, P.G.; Brodde, M.F.; Steiner, M.; Savion, N.; Varon, D.; Sixma, J.J.; Van Aken, H.; Kehrel, B.E. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J., 2003, 17(11), 1490-1492.
52. Stomski, F.C.; Gani, J.S.; Bates, R.C.; Burns, G.F. Adhesion to thrombospondin by human embryonic fibroblasts is mediated by multiple receptors and includes a role for glycoprotein 88 (CD36). Exp. Cell Res., 1992, 198(1), 85-92.
53. Esemuede, N.; Lee, T.; Pierre-Paul, D.; Sumpio, B.E.; Gahtan, V. The role of thrombospondin-1 in human disease. J. Surg. Res., 2004, 122(1), 135-142.
54. Moura, R.; Tjwa, M.; Vandervoort, P.; Van Kerckhoven, S.; Holvoet, P.; Hoylaerts, M.F. Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE-/-mice. Circ. Res., 2008, 103(10), 1181-1189.
55. Wight, T.N.; Raugi, G.J.; Mumby, S.M.; Bornstein, P. Light microscopic immunolocation of thrombospondin in human tissues. J. Histochem. Cytochem., 1985, 33(4), 295-302.
56. Bonnefoy, A.; Hoylaerts, M.F. Thrombospondin-1 in von Wille-brand factor function. Curr. Drug Targets, 2008, 9(10), 822-832.
57. Leung, L.L.; Li, W.X.; McGregor, J.L.; Albrecht, G.; Howard, R.J. CD36 peptides enhance or inhibit CD36-thrombospondin binding.A two-step process of ligand-receptor interaction. J. Biol. Chem., 1992, 267(25), 18244-18250.
58. Baranova, I.N.; Bocharov, A.V.; Vishnyakova, T.G.; Kurlander, R.; Chen, Z.; Fu, D.; Arias, I.M.; Csako, G.; Patterson, A.P.; Egger-man, T.L. CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J. Biol. Chem., 2010, 285(11), 8492-8506.
59. Agbanyo, F.R.; Sixma, J.J.; de Groot, P.G.; Languino, L.R.; Plow, E.F. Thrombospondin-platelet interactions.Role of divalent cations, wall shear rate, and platelet membrane glycoproteins. J. Clin. Invest., 1993, 92(1), 288-296.
60. Bonnefoy, A.; Hantgan, R.; Legrand, C.; Frojmovic, M.M. A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor. J. Biol. Chem., 2001, 276(8), 5605-5612.
61. Chung, J.; Wang, X.Q.; Lindberg, F.P.; Frazier, W.A. Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in αIIß1-mediated platelet activation. Blood, 1999, 94(2), 642-648.
62. Isenberg, J.S.; Romeo, M.J.; Yu, C; Yu, C.K.; Nghiem, K.; Mon-sale, J.; Rick, M.E.; Wink, D.A.; Frazier, W.A.; Roberts, D.D. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood, 2008, 111(2), 613-623.
63. Saumet, A.; de Jesus, N.; Legrand, C.; Dubernard, V. Association of thrombospondin-1 with the actin cytoskeleton of human throm-bin-activated platelets through an aIIbb3-or CD36-independent mechanism. Biochem. J., 2002, 363(Pt 3), 473-782.
64. Nergiz-Unal, R.; Kuijpers, M.J.; Munnix, I.C; Glatz, J.F.; Heemskerk, J.W. Outside-in signaling induced by thrombospondin-1 enhances thrombus formation: involvement of CD36. J. Thromb. Haemost., 2009, 7(Suppl. 2), PP-TH-012.
65. Tulasne, D.; Judd, B.A.; Johansen, M.; Asazuma, N.; Best, D.; Brown, E.J.; Kahn, M.; Koretzky, G.A.; Watson, S.P. C-terminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor γ-chain-associated signaling pathway and by agglutination. Blood, 2001, 98(12), 3346-3352.
66. Miao, W.M.; Vasile, E.; Lane, W.S.; Lawler, J. CD36 associates with CD9 and integrins on human blood platelets. Blood, 2001, 97(6), 1689-1696.
67. Davis, A.K.; Makar, R.S.; Stowell, C.P.; Kuter, D.J.; Dzik, W.H. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS 13. Transfusion, 2009, 49(2), 206-213.
68. Isenberg, J.S.; Wink, D.A.; Roberts, D.D. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc. Res., 2006, 71(4), 785-793.
69. Isenberg, J.S.; Yu, C; Roberts, D.D. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem. Pharmacol., 2008, 75(4), 875-882.
70. Roberts, W.; Magwenzi, S.; Aburima, A.; Naseem, K.M. Throm-binspondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood, 2010, [Epub ahead of print].
71. Yang, Q.; Tian, Y.; Liu, S.; Zeine, R.; Chlenski, A.; Salwen, H.R.; Henkin, J.; Cohn, S.L. Thrombospondin-1 peptide ABT-510 com-bined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res., 2007, 67(4), 1716-1724.
72. Endemann, G.; Stanton, L.W.; Madden, K.S.; Bryant, C.M.; White, R.T.; Protter, A.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem., 1993, 268(16), 11811-11816.
73. Sun, B.; Boyanovsky, B.B.; Connelly, M.A.; Shridas, P.; van der Westhuyzen, D.R.; Webb, N.R. Distinct mechanisms for oxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI. J. Lipid Res., 2007, 48(12), 2560-2570.
74. Martin, C.A.; Longman, E.; Wooding, C.; Hoosdally, S.J.; Ali, S.; Aitman, T.J.; Gutmann, D.A.; Freemont, P.S.; Byrne, B.; Linton, K.J. CD36, a class B scavenger receptor, functions as a monomer to bind acetylated and oxidized low-density lipoproteins. Protein Sci., 2007, 16(11), 2531-2541.
75. Thorne, R.F.; Mhaidat, N.M.; Ralston, K.J.; Burns, G.F. CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett., 2007, 581(6), 1227-1232.
76. Yamashita, S.; Hirano, K.; Kuwasako, T.; Janabi, M.; Toyama, Y.; Ishigami, M.; Sakai, N. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis: insights from CD36-deficient patients. Mol. Cell Biochem., 2007, 299(1-2), 19-22.
77. Podrez, E.A.; Febbraio, M.; Sheibani, N.; Schmitt, D.; Silverstein, R.L.; Hajjar, D.P.; Cohen, P.A.; Frazier, W.A.; Hoff, H.F.; Hazen, S.L. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest., 2000, 105(8), 1095-1108.
78. Podrez, E.A.; Poliakov, E.; Shen, Z.; Zhang, R.; Deng, Y.; Sun, M.; Finton, P.J.; Shan, L.; Gugiu, B.; Fox, P.L.; Hoff, H.F.; Salomon, R.G.; Hazen, S.L. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem., 2002, 277(41), 38503-38516.
79. Podrez, E.A.; Byzova, T.V.; Febbraio, M.; Salomon, R.G.; Ma, Y.; Valiyaveettil, M.; Poliakov, E.; Sun, M.; Finton, P.J.; Curtis, B.R.; Chen, J.; Zhang, R.; Silverstein, R.L.; Hazen, S.L. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic pheno-type. Nat. Med., 2007, 13(9), 1086-1095.
80. Greenberg, M.E.; Sun, M.; Zhang, R.; Febbraio, M.; Silverstein, R.; Hazen, S.L. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med., 2006, 203(12), 2613-2625.
81. Gao, D.; Ashraf, M.Z.; Kar, N.S.; Lin, D.; Sayre, L.M.; Podrez, E.A. Structural basis for the recognition of oxidized phospholipids in oxidized low density lipoproteins by class B scavenger receptors CD36 and SR-BI. J. Biol. Chem., 2010, 285(7), 4447-4454.
82. Hartwich, J.; Dembinska-Kiec, A.; Gruca, A.; Motyka, M.; Par-tyka, L.; Skrzeczynska, J.; Bzowska, M.; Pryjma, J.; Huber, J.; Leitinger, N.; Schmitz, G. Regulation of platelet adhesion by oxidized lipoproteins and oxidized phospholipids. Platelets, 2002, 13(3), 141-151.
83. Korporaal, S.J.; Van Eck, M.; Adelmeijer, J.; Ijsseldijk, M.; Out, R.; Lisman, T.; Lenting, P.J.; Van Berkel, T.J.; Akkerman, J.W. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler. Thromb. Vasc. Biol., 2007, 27(11), 2476-2483.
84. Luangrath, V.; Brodeur, M.R.; Rhainds, D.; Brissette, L. Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo. Arterioscler. Thromb. Vasc. Biol., 2008, 28(7), 1290-1295.
85. Maschberger, P.; Bauer, M.; Baumann-Siemons, J.; Zangl, K.J.; Negrescu, E.V.; Reininger, A.J.; Siess, W. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lys-ophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J. Biol. Chem., 2000, 275(25), 19159-19166.
86. Korporaal, S.J.; Gorter, G.; van Rijn, H.J.; Akkerman, J.W. Effect of oxidation on the platelet-activating properties of low-density lipoprotein. Arterioscler. Thromb. Vasc Biol., 2005, 25(4), 867-872.
87. Zhao, M.; Liu, Y.; Wang, X.; New, L.; Han, J.; Brunk, U.T. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. APMIS, 2002, 110(6), 458-468.
88. Lim, H.J.; Lee, S.; Lee, K.S.; Park, J.H.; Jang, Y.; Lee, E.J.; Park, H.Y. PPARgamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs. Prostaglandins Other Lipid Mediat., 2006, 80(3-4), 165-174.
89. Chen, K.; Febbraio, M.; Li, W.; Silverstein, R.L. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ. Res., 2008, 102(12), 1512-1519.
90. Assinger, A.; Schmid, W.; Eder, S.; Schmid, D.; Koller, E.; Volf, I. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett., 2008, 582(5), 778-784.
91. Ghosh, A.; Li, W.; Febbraio, M.; Espinola, R.G.; McCrae, K.R.; Cockrell, E.; Silverstein, R.L. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J. Clin. Invest., 2008, 118(5), 1934-1943.
92. Collins, R.F.; Touret, N.; Kuwata, H.; Tandon, N.N.; Grinstein, S.; Trimble, W.S. Uptake of oxidized low density lipoprotein by CD36 occurs by an actin-dependent pathway distinct from macropinocy-tosis. J. Biol. Chem., 2009, 284(44), 30288-30297.
93. Akkerman, J.W.N. From low-density lipoprotein to platelet activation. Int. J. Biochem. Cell Biol., 2008, 40(11), 2374-2378.
94. Morii, T.; Ohno, Y.; Kato, N.; Hirose, H.; Kawabe, H.; Hirao, K.; Eguchi, T.; Maruyama, T.; Hayashi, M.; Saito, I.; Yazaki, Y.; Saruta, T. CD36 single nucleotide polymorphism is associated with variation in low-density lipoprotein-cholesterol in young Japanese men. Biomarkers, 2009, 14(4), 207-212.
95. Calvo, D.; Gomez-Coronado, D.; Suarez, Y.; Lasuncion, M.A.; Vega, M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid Res., 1998, 39(4), 777-788.
96. Marleau, S.; Harb, D.; Bujold, K.; Avallone, R.; Iken, K.; Wang, Y.; Demers, A.; Sirois, M.G.; Febbraio, M.; Silverstein, R.L.; Tremblay, A.; Ong, H. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J., 2005, 19(13), 1869-1871.
97. Avallone, R.; Demers, A.; Rodrigue-Way, A.; Bujold, K.; Harb, D.; Anghel, S.; Wahli, W.; Marleau, S.; Ong, H.; Tremblay, A. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway. Mol. Endocrinol., 2006, 20(12), 3165-78.
98. Patel, S.N.; Serghides, L.; Smith, T.G.; Febbraio, M.; Silverstein, R.L.; Kurtz, T.W.; Pravenec, M.; Kain, K.C. CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages. J. Infect. Dis., 2004, 189(2), 204-213.
99. Coburn, C.T.; Knapp, F.F.; Febbraio, M.; Beets, A.L.; Silverstein, R.L.; Abumrad, N.A. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J. Biol. Chem., 2000, 275(42), 32523-32529.
100. Koonen, D.P.; Glatz, J.F.; Bonen, A.; Luiken, J.J. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta, 2005, 1736(3), 163-80.
101. Alexander Aguilera, A.; Hernandez Diaz, G.; Lara Barcelata, M.; Angulo Guerrero, O.; Oliart Ros, R.M. Induction of CD36 expression elicited by fish oil PUFA in spontaneously hypertensive rats. J. Nutr. Biochem., 2006, 17(11), 760-765.
102. Glatz, J.F.; Luiken, J.J.; Bonen, A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol. Rev., 2010, 90(1), 367-417.
103. Pietsch, A.; Weber, C.; Goretzki, M.; Weber, P.C.; Lorenz, R.L. N-3 but not N-6 fatty acids reduce the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Cell Biochem. Funct., 1995, 13(3), 211-216.
104. Zhu, W.; Smart, E.J. Myristic acid stimulates endothelial nitric-oxide synthase in a CD36-and an AMP kinase-dependent manner. J. Biol. Chem., 2005, 280(33), 29543-29550.
105. Coort, S.L.; Willems, J.; Coumans, W.A.; van der Vusse, G.J.; Bonen, A.; Glatz, J.F.; Luiken, J.J. Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol. Cell Biochem., 2002, 239(1-2), 213-219.
106. Isenberg, J.S.; Jia, Y.; Fukuyama, J.; Switzer, C.H.; Wink, D.A.; Roberts, D.D. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J. Biol. Chem., 2007, 282(21), 15404-15415.
107. Coburn, C.T.; Hajri, T.; Ibrahimi, A.; Abumrad, N.A. Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues. J. Mol. Neurosci., 2001, 16(2-3), 117-121.
108. Harmon, C.M.; Abumrad, N.A. Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins: isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J. Membr. Biol., 1993, 133(1), 43-49.
109. Drover, V.A.; Nguyen, D.V.; Bastie, C.C.; Darlington, Y.F.; Abumrad, N.A.; Pessin, J.E.; London, E.; Sahoo, D.; Phillips, M.C. CD36 mediates both cellular uptake of very long chain fatty acids and their intestinal absorption in mice. J. Biol. Chem., 2008, 283(19), 13108-13115.
110. Laugerette, F.; Passilly-Degrace, P.; Patris, B.; Niot, I.; Febbraio, M.; Montmayeur, J.P.; Besnard, P. CD36 involvement in orosen-sory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J. Clin. Invest., 2005, 115(11), 3177-3184.
111. Gaillard, D.; Laugerette, F.; Darcel, N.; El-Yassimi, A.; Passilly-Degrace, P.; Hichami, A.; Khan, N.A.; Montmayeur, J.P.; Besnard, P. The gustatory pathway is involved in CD36-mediated orosen-sory perception of long-chain fatty acids in the mouse. FASEB J., 2008, 22(5), 1458-68.
112. Ibrahimi, A.; Sfeir, Z.; Magharaie, H.; Amri, E.Z.; Grimaldi, P.; Abumrad, N.A. Expression of the CD36 homolog (FAT) in fibro-blast cells: effects on fatty acid transport. Proc. Natl. Acad. Sci. USA, 1996, 93(7), 2646-2651.
113. Nickerson, J.G.; Alkhateeb, H.; Benton, C.R.; Lally, J.; Nickerson, J.; Han, X.X.; Wilson, M.H.; Jain, S.S.; Snook, L.A.; Glatz, J.F.; Chabowski, A.; Luiken, J.J.; Bonen, A. Greater transport efficiencies of the membrane fatty acid transporters FAT/CD36 and FATP4 compared with FABPpm and FATP1 and differential effects on fatty acid esterification and oxidation in rat skeletal muscle. J. Biol. Chem., 2009, 284(24), 16522-16530.
114. Eyre, N.S.; Cleland, L.G.; Mayrhofer, G. FAT/CD36 expression alone is insufficient to enhance cellular uptake of oleate. Biochem. Biophys. Res. Commun., 2008, 370(3), 404-409.
115. Eda, S.; Eda, K.; Prudhomme, J.G.; Sherman, I.W. Inhibitory activity of human lactoferrin and its peptide on chondroitin sulfate A-, CD36-, and thrombospondin-mediated cytoadherence of plasmodium falciparum-infected erythrocytes. Blood, 1999, 94(1), 326-332.
116. Baruch, D.I.; Ma, X.C.; Pasloske, B.; Howard, R.J.; Miller, L.H. CD36 peptides that block cytoadherence define the CD36 binding region for Plasmodium falciparum-infected erythrocytes. Blood, 1999, 94(6), 2121-2127.
117. Aitman, T.J.; Glazier, A.M.; Wallace, C.A.; Cooper, L.D.; Nor-sworthy, P.J.; Wahid, F.N.; Al-Majali, K.M.; Trembling, P.M.; Mann, C.J.; Shoulders, C.C.; Graf, D.; St Lezin, E.; Kurtz, T.W.; Kren, V.; Pravenec, M.; Ibrahimi, A.; Abumrad, N.A.; Stanton, L.W.; Scott, J. Identification of CD36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet., 1999, 21(1), 76-83.
118. Englyst, N.A.; Taube, J.M.; Aitman, T.J.; Baglin, T.P.; Byrne, C.D. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes, 2003, 52(5), 1248-1255.
119. Pravenec, M.; Zidek, V.; Simakova, M.; Kren, V.; Krenova, D.; Horky, K.; Jachymova, M.; Mikova, B.; Kazdova, L.; Aitman, T.J.; Churchill, P.C.; Webb, R.C.; Hingarh, N.H.; Yang, Y.; Wang, J.M.; Lezin, E.M.; Kurtz, T.W. Genetics of CD36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J. Clin. Invest., 1999, 103(12), 1651-1657.
120. Goudriaan, J.R.; Dahlmans, V.E.; Febbraio, M.; Teusink, B.; Romijn, J.A.; Havekes, L.M.; Voshol, P.J. Intestinal lipid absorption is not affected in CD36 deficient mice. Mol. Cell Biochem., 2002, 239(1-2), 199-202.
121. Bonen, A.; Han, X.X.; Habets, D.D.; Febbraio, M.; Glatz, J.F.; Luiken, J.J. A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin-and AICAR-stimulated fatty acid metabolism. Am. J. Physiol., 2007, 292(6), E1740-E1749.
122. Febbraio, M.; Abumrad, N.A.; Hajjar, D.P.; Sharma, K.; Cheng, W.; Pearce, S.F.; Silverstein, R.L. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem., 1999, 274(27), 19055-19062.
123. Guy, E.; Kuchibhotla, S.; Silverstein, R.; Febbraio, M. Continued inhibition of atherosclerotic lesion development in long term western diet fed CD36-/-/apoE-/-mice. Atherosclerosis, 2007, 192(1), 123-130.
124. Lipsky, R.H.; Ikeda, H.; Medved, E.S. A dinucleotide repeat in the third intron of CD36. Hum. Mol. Genet., 1994, 3(1), 217.
125. Kashiwagi, H.; Tomiyama, Y.; Kosugi, S.; Shiraga, M.; Lipsky, R.H.; Nagao, N.; Kanakura, Y.; Kurata, Y.; Matsuzawa, Y. Family studies of type II CD36 deficient subjects: linkage of a CD36 allele to a platelet-specific mRNA expression defect(s) causing type II CD36 deficiency. Thromb. Haemost., 1995, 74(2), 758-763.
126. Kashiwagi, H.; Tomiyama, Y.; Nozaki, S.; Kiyoi, T.; Tadokoro, S.; Matsumoto, K.; Honda, S.; Kosugi, S.; Kurata, Y.; Matsuzawa, Y. Analyses of genetic abnormalities in type I CD36 deficiency in Japan: identification and cell biological characterization of two novel mutations that cause CD36 deficiency in man. Hum. Genet., 2001, 108(6), 459-466.
127. Hanawa, H.; Watanabe, K.; Nakamura, T.; Ogawa, Y.; Toba, K.; Fuse, I.; Kodama, M.; Kato, K.; Fuse, K.; Aizawa, Y. Identification of cryptic splice site, exon skipping, and novel point mutations in type I CD36 deficiency. J. Med. Genet., 2002, 39(4), 286-291.
128. Imai, M.; Tanaka, T.; Kintaka, T.; Ikemoto, T.; Shimizu, A.; Kitaura, Y. Genomic heterogeneity of type II CD36 deficiency. Clin. Chim. Acta, 2002, 321(1-2), 97-106.
129. Kashiwagi, H.; Tomiyama, Y.; Kosugi, S.; Shiraga, M.; Lipsky, R.H.; Kanayama, Y.; Kurata, Y.; Matsuzawa, Y. Identification of molecular defects in a subject with type I CD36 deficiency. Blood, 1994, 83(12), 3545-3552.
130. Yamamoto, N.; Akamatsu, N.; Sakuraba, H.; Yamazaki, H.; Ta-noue, K. Platelet glycoprotein IV (CD36) deficiency is associated with the absence (type I) or the presence (type II) of glycoprotein IV on monocytes. Blood, 1994, 83(2), 392-397.
131. Fukuchi, K.; Nozaki, S.; Yoshizumi, T.; Hasegawa, S.; Uehara, T.; Nakagawa, T.; Kobayashi, T.; Tomiyama, Y.; Yamashita, S.; Ma-tsuzawa, Y.; Nishimura, T. Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency). J. Nucl. Med., 1999, 40(2), 239-243.
132. Hirano, K.; Kuwasako, T.; Nakagawa-Toyama, Y.; Janabi, M.; Yamashita, S.; Matsuzawa, Y. Pathophysiology of human genetic CD36 deficiency. Trends. Cardiovasc. Med., 2003, 13(4), 136-141.
133. Yamamoto, N.; Ikeda, H.; Tandon, N.N.; Herman, J.; Tomiyama, Y.; Mitani, T.; Sekiguchi, S.; Lipsky, R.; Kralisz, U.; Jamieson, G.A. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka-platelets lack detectable GPIV (CD36). Blood, 1990, 76(9), 1698-1703.
134. Watanabe, K.; Ohta, Y.; Toba, K.; Ogawa, Y.; Hanawa, H.; Hiro-kawa, Y.; Kodama, M.; Tanabe, N.; Hirono, S.; Ohkura, Y.; Naka-mura, Y.; Kato, K.; Aizawa, Y.; Fuse, I.; Miyajima, S.; Kusano, Y.; Nagamoto, T.; Hasegawa, G.; Naito, M. Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Ann. Nucl. Med., 1998, 12(5), 261-266.
135. Teraguchi, M.; Ikemoto, Y.; Unishi, G.; Ohkohchi, H.; Kobayashi, Y. Influence of CD36 deficiency on heart disease in children. Circ. J., 2004, 68(5), 435-438.
136. Yanai, H.; Chiba, H.; Morimoto, M.; Abe, K.; Fujiwara, H.; Fuda, H.; Hui, S.P.; Takahashi, Y.; Akita, H.; Jamieson, G.A.; Kobaya-shi, K.; Matsuno, K. Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol. Am. J. Med. Genet., 2000, 93(4), 299-304.
137. Miyaoka, K.; Kuwasako, T.; Hirano, K.; Nozaki, S.; Yamashita, S.; Matsuzawa, Y. CD36 deficiency associated with insulin resistance. Lancet, 2001, 357(9257), 686-687.
138. Kamiya, M.; Nakagomi, A.; Tokita, Y.; Yasutake, M.; Kusama, Y.; Takayama, M.; Takano, T. Type I CD36 deficiency associated with metabolic syndrome and vasospastic angina: a case report. J. Car-diol., 2006, 48(1), 41-44.
139. Chen, M.; Yang, Y.; Braunstein, E.; Georgeson, K.E.; Harmon, C.M. Gut expression and regulation of FAT/CD36: possible role in fatty acid transport in rat enterocytes. Am. J. Physiol., 2001, 281(5), E916-923.
140. Nassir, F.; Wilson, B.; Han, X.; Gross, R.W.; Abumrad, N.A. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J. Biol. Chem., 2007, 282(27), 19493-19501.
141. Drover, V.A.; Ajmal, M.; Nassir, F.; Davidson, N.O.; Nauli, A.M.; Sahoo, D.; Tso, P.; Abumrad, N.A. CD36 deficiency impairs intestinal lipid secretion and clearance of chylomicrons from the blood. J. Clin. Invest., 2005, 115(5), 1290-1297.
142. Bonen, A.; Tandon, N.N.; Glatz, J.F.; Luiken, J.J.; Heigenhauser, G.J. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int. J. Obes., 2006, 30(6), 877-883.
143. Koonen, D.P.; Jacobs, R.L.; Febbraio, M.; Young, M.E.; Soltys, C.L.; Ong, H.; Vance, D.E.; Dyck, J.R. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes, 2007, 56(12), 2863-2871.
144. Luiken, J.J.; Coort, S.L.; Koonen, D.P.; Bonen, A.; Glatz, J.F. Signalling components involved in contraction-inducible substrate uptake into cardiac myocytes. Proc. Nutr. Soc., 2004, 63(2), 251-258.
145. Hajri, T.; Han, X.X.; Bonen, A.; Abumrad, N.A. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J. Clin. Invest., 2002, 109(10), 1381-1389.
146. Handberg, A.; Levin, K.; Hojlund, K.; Beck-Nielsen, H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation, 2006, 114(11), 1169-1176.
147. Glintborg, D.; Hojlund, K.; Andersen, M.; Henriksen, J.E.; BeckNielsen, H.; Handberg, A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care, 2008, 31(2), 328-334.
148. Handberg, A.; Lopez-Bermejo, A.; Bassols, J.; Vendrell, J.; Ricart, W.; Fernandez-Real, J.M. Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men. Diab. Vasc. Dis. Res., 2009, 6(1), 15-20.
149. Handberg, A.; Norberg, M.; Stenlund, H.; Hallmans, G.; Atter-mann, J.; Eriksson, J.W. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. J. Clin. Endocrinol. Metab., 2010, 95(4), 1939-1946.
150. Jimenez-Dalmaroni, M.J.; Xiao, N.; Corper, A.L.; Verdino, P.; Ainge, G.D.; Larsen, D.S.; Painter, G.F.; Rudd, P.M.; Dwek, R.A.; Hoebe, K.; Beutler, B.; Wilson, I.A. Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. Plos One, 2009, 4(10), e7411.
151. Podrez, E.A.; Poliakov, E.; Shen, Z.; Zhang, R.; Deng, Y.; Sun, M.; Finton, P.J.; Shan, L.; Febbraio, M.; Hajjar, D.P.; Silverstein, R.L.; Hoff, H.F.; Salomon, R.G.; Hazen, S.L. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem., 2002, 277(41), 38517-38523.
152. D'Archivio, M.; Scazzocchio, B.; Filesi, C.; Vari, R.; Maggiorella, M.T.; Sernicola, L.; Santangelo, C.; Giovannini, C.; Masella, R. Oxidized LDL up-regulates CD36 expression by the Nrf2 pathway in 3T3-L1 preadipocytes. FEBS Lett., 2008, 582(15), 2291-2298.
153. Rahaman, S.O.; Lennon, D.J.; Febbraio, M.; Podrez, E.A.; Hazen, S.L.; Silverstein, R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab., 2006, 4(3), 211-221.
154. Katayama, I.; Hotokezaka, Y.; Matsuyama, T.; Sumi, T.; Naka-mura, T. Ionizing radiation induces macrophage foam cell formation and aggregation through JNK-dependent activation of CD36 scavenger receptors. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70(3), 835-846.
155. Kennedy, D.J.; Kuchibhotla, S.D.; Guy, E.; Park, Y.M.; Nimako, G.; Vanegas, D.; Morton, R.E.; Febbraio, M. Dietary cholesterol plays a role in CD36-mediated atherogenesis in LDLR-knockout mice. Arterioscler. Thromb. Vasc. Biol., 2009, 29(10), 1481-1487.
156. Martin-Fuentes, P.; Civeira, F.; Recalde, D.; Garcia-Otin, A.L.; Jarauta, E.; Marzo, I.; Cenarro, A. Individual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory response. J. Immunol., 2007, 179(5), 3242-3248.
157. Silverstein, R.L. Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve. Clin. J. Med., 2009, 76, S27-30.
158. Nagarajan, S. Anti-oxLDL IgG blocks oxLDL interaction with CD36, but promotes FcgammaR, CD32A-dependent inflammatory cell adhesion. Immunol. Lett., 2007, 108(1), 52-61.
159. Harb, D.; Bujold, K.; Febbraio, M.; Sirois, M.G.; Ong, H.; Mar-leau, S. The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc. Res., 2009, 83(1), 42-51.
160. Cho, S.; Park, E.M.; Febbraio, M.; Anrather, J.; Park, L.; Rac-chumi, G.; Silverstein, R.L.; Iadecola, C. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J. Neurosci., 2005, 25(10), 2504-2512.
161. Cho, S.; Szeto, H.H.; Kim, E.; Kim, H.; Tolhurst, A.T.; Pinto, J.T. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J. Biol. Chem., 2007, 282(7), 4634-4642.
162. Kim, E.; Tolhurst, A.T.; Qin, L.Y.; Chen, X.Y.; Febbraio, M.; Cho, S. CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. J. Neurosci., 2008, 28(18), 4661-4670.
163. Bochkov, V.N.; Mechtcheriakova, D.; Lucerna, M.; Huber, J.; Malli, R.; Graier, W.F.; Hofer, E.; Binder, B.R.; Leitinger, N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca2+/NFAT. Blood, 2002, 99(1), 199-206.
164. Barnwell, J.W.; Asch, A.S.; Nachman, R.L.; Yamaya, M.; Aikawa, M.; Ingravallo, P. A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. J. Clin. Invest., 1989, 84(3), 765-772.
165. Cserti-Gazdewich, C.M.; Dzik, W.H.; Dorn, M.E.; Quagliaroli, R.O.; Xu, S.; Ssewanyana, I.; Nayyar, R.; Preffer, F.I. Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. Cytometry B. Clin. Cytom., 2009, 76(2), 127-134.
166. Isenberg, J.S.; Calzada, M.J.; Zhou, L.; Guo, N.; Lawler, J.; Wang, X.Q.; Frazier, W.A.; Roberts, D.D. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol., 2005, 24(2), 110-123.
167. Xu, X.; Pang, J.; Yin, H.; Li, M.; Hao, W.; Chen, C.; Cao, J.M. Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat. Am. J. Physiol., 2007, 293(5), H2952-H2958.
168. Brinkmann, J.F.; Abumrad, N.A.; Ibrahimi, A.; van der Vusse, G.J.; Glatz, J.F. New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36. Biochem. J., 2002, 367(Pt 3), 561-570.
169. Kontrova, K.; Zidkova, J.; Bartos, B.; Skop, V.; Sajdok, J.; Kazdova, L.; Mikulik, K.; Mlejnek, P.; Zidek, V.; Pravenec, M. CD36 regulates fatty acid composition and sensitivity to insulin in 3T3-L1 adipocytes. Physiol. Res., 2007, 56(4), 493-496.
170. Unno, Y.; Sakai, M.; Sakamoto, Y.; Kuniyasu, A.; Nagai, R.; Na-kayama, H.; Horiuchi, S. Glycolaldehyde-modified bovine serum albumin downregulates leptin expression in mouse adipocytes via a CD36-mediated pathway. Ann. N.Y. Acad. Sci., 2005, 1043, 696-701.
171. Unno, Y.; Sakai, M.; Sakamoto, Y.; Kuniyasu, A.; Nakayama, H.; Nagai, R.; Horiuchi, S. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem. Biophys. Res. Commun., 2004, 325(1), 151-156.
172. Bokor, S.; Legry, V.; Meirhaeghe, A.; Ruiz, J.R.; Mauro, B.; Widhalm, K.; Manios, Y.; Amouyel, P.; Moreno, L.A.; Molnar, D.; Dallongeville, J. Single-nucleotide polymorphism of CD36 locus and obesity in European adolescents. Obesity (Silver Spring), 2009, 18(7), 1398-1403.
173. Wieclawska, B.; Rozalski, M.; Trojanowski, Z.; Watala, C. Modulators of intraplatelet calcium concentration affect the binding of thrombospondin to blood platelets in healthy donors and patients with type 2 diabetes mellitus. Eur. J. Haematol., 2001, 66(6), 396-403.
174. Huang, M.M.; Bolen, J.B.; Barnwell, J.W.; Shattil, S.J.; Brugge, J.S. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc. Natl. Acad. Sci. USA, 1991, 88(17), 7844-7848.
175. Dorahy, D.J.; Lincz, L.F.; Meldrum, C.J.; Burns, G.F. Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem. J., 1996, 319, 67-72.
176. Hirao, A.; Hamaguchi, I.; Suda, T.; Yamaguchi, N. Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of CD36-anchored Lyn tyrosine kinase in thrombin-stimulated platelets. EMBO J., 1997, 16(9), 2342-2351.
177. Hoebe, K.; Georgel, P.; Rutschmann, S.; Du, X.; Mudd, S.; Crozat, K.; Sovath, S.; Shamel, L.; Hartung, T.; Zahringer, U.; Beutler, B. CD36 is a sensor of diacylglycerides. Nature, 2005, 433(7025), 523-527.